Vitamin D status is a determinant of atorvastatin effect on carotid intima medial thickening progression rate in children with lupus: An Atherosclerosis Prevention in Pediatric Lupus Erythematosus (APPLE) substudy

APPLE investigators

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Objective: Epidemiological associations suggest that vitamin D status may play a role in inflammation and progression of atherosclerosis. Using frozen serum, carotid intima medial thickness (CIMT) measurements and other existing data from the Atherosclerosis Prevention in Pediatric Lupus Erythematosus (APPLE) trial, we assessed interactions between serum 25-hydroxyvitamin D (25(OH)D), atorvastatin randomisation and CIMT progression rate. Methods: Participants in the 3-year APPLE trial were randomised to placebo or atorvastatin and CIMT progression rate was measured. Baseline frozen serum was used to measure 25(OH)D concentrations. Mixed effect longitudinal models for CIMT progression at 3 years were used to evaluate interaction between vitamin D deficiency (serum 25(OH)D

Original languageEnglish (US)
Article numbere000037
JournalLupus Science and Medicine
Volume1
Issue number1
DOIs
StatePublished - Jun 1 2014

Fingerprint

Vitamin D
Atherosclerosis
Pediatrics
Serum
Vitamin D Deficiency
Random Allocation
Placebos
Inflammation
Atorvastatin Calcium

ASJC Scopus subject areas

  • Medicine(all)
  • Immunology

Cite this

@article{04d21a2580e84e49959b03237f7af545,
title = "Vitamin D status is a determinant of atorvastatin effect on carotid intima medial thickening progression rate in children with lupus: An Atherosclerosis Prevention in Pediatric Lupus Erythematosus (APPLE) substudy",
abstract = "Objective: Epidemiological associations suggest that vitamin D status may play a role in inflammation and progression of atherosclerosis. Using frozen serum, carotid intima medial thickness (CIMT) measurements and other existing data from the Atherosclerosis Prevention in Pediatric Lupus Erythematosus (APPLE) trial, we assessed interactions between serum 25-hydroxyvitamin D (25(OH)D), atorvastatin randomisation and CIMT progression rate. Methods: Participants in the 3-year APPLE trial were randomised to placebo or atorvastatin and CIMT progression rate was measured. Baseline frozen serum was used to measure 25(OH)D concentrations. Mixed effect longitudinal models for CIMT progression at 3 years were used to evaluate interaction between vitamin D deficiency (serum 25(OH)D",
author = "{APPLE investigators} and Robinson, {Angela Byun} and Vin Tangpricha and Eric Yow and Reut Gurion and Schanberg, {Laura E.} and McComsey, {Grace A.} and Stacy Ardoin and Dewitt, {Esi Morgan} and Rabinovich, {C. Egla} and Janet Ellis and Kelly Mieszkalski and Janet Wootton and Peter Chira and Joyce Hsu and Tzielan Lee and Christy Sandborg and Jan Perea and Beth Gottlieb and Patricia Irigoyen and Jennifer Luftig and Shaz Siddiqi and Zhen Ni and Marilynn Orlando and Eileen Pagano and Andrew Eichenfield and Lisa Imundo and Deborah Levy and Philip Kahn and Candido Batres and Digna Cabral and Haines, {Kathleen A.} and Yukiko Kimura and Li, {Suzanne C.} and Jennifer Weiss and Riordan, {Mary Ellen} and Beena Vaidya and {Von Scheven}, Emily and Michelle Mietus-Snyder and Earl Silverman and Lawrence Ng and Suzanne Bowyer and Susan Ballinger and Thomas Klausmeier and Debra Hinchman and Andrea Hudgins and Marilynn Punaro and Shirley Henry and Shuzen Zhang and Singer, {Nora G.} and Thomas Mason",
year = "2014",
month = "6",
day = "1",
doi = "10.1136/lupus-2014-000037",
language = "English (US)",
volume = "1",
journal = "Lupus Science and Medicine",
issn = "2053-8790",
publisher = "BMJ Publishing Group",
number = "1",

}

TY - JOUR

T1 - Vitamin D status is a determinant of atorvastatin effect on carotid intima medial thickening progression rate in children with lupus

T2 - An Atherosclerosis Prevention in Pediatric Lupus Erythematosus (APPLE) substudy

AU - APPLE investigators

AU - Robinson, Angela Byun

AU - Tangpricha, Vin

AU - Yow, Eric

AU - Gurion, Reut

AU - Schanberg, Laura E.

AU - McComsey, Grace A.

AU - Ardoin, Stacy

AU - Dewitt, Esi Morgan

AU - Rabinovich, C. Egla

AU - Ellis, Janet

AU - Mieszkalski, Kelly

AU - Wootton, Janet

AU - Chira, Peter

AU - Hsu, Joyce

AU - Lee, Tzielan

AU - Sandborg, Christy

AU - Perea, Jan

AU - Gottlieb, Beth

AU - Irigoyen, Patricia

AU - Luftig, Jennifer

AU - Siddiqi, Shaz

AU - Ni, Zhen

AU - Orlando, Marilynn

AU - Pagano, Eileen

AU - Eichenfield, Andrew

AU - Imundo, Lisa

AU - Levy, Deborah

AU - Kahn, Philip

AU - Batres, Candido

AU - Cabral, Digna

AU - Haines, Kathleen A.

AU - Kimura, Yukiko

AU - Li, Suzanne C.

AU - Weiss, Jennifer

AU - Riordan, Mary Ellen

AU - Vaidya, Beena

AU - Von Scheven, Emily

AU - Mietus-Snyder, Michelle

AU - Silverman, Earl

AU - Ng, Lawrence

AU - Bowyer, Suzanne

AU - Ballinger, Susan

AU - Klausmeier, Thomas

AU - Hinchman, Debra

AU - Hudgins, Andrea

AU - Punaro, Marilynn

AU - Henry, Shirley

AU - Zhang, Shuzen

AU - Singer, Nora G.

AU - Mason, Thomas

PY - 2014/6/1

Y1 - 2014/6/1

N2 - Objective: Epidemiological associations suggest that vitamin D status may play a role in inflammation and progression of atherosclerosis. Using frozen serum, carotid intima medial thickness (CIMT) measurements and other existing data from the Atherosclerosis Prevention in Pediatric Lupus Erythematosus (APPLE) trial, we assessed interactions between serum 25-hydroxyvitamin D (25(OH)D), atorvastatin randomisation and CIMT progression rate. Methods: Participants in the 3-year APPLE trial were randomised to placebo or atorvastatin and CIMT progression rate was measured. Baseline frozen serum was used to measure 25(OH)D concentrations. Mixed effect longitudinal models for CIMT progression at 3 years were used to evaluate interaction between vitamin D deficiency (serum 25(OH)D

AB - Objective: Epidemiological associations suggest that vitamin D status may play a role in inflammation and progression of atherosclerosis. Using frozen serum, carotid intima medial thickness (CIMT) measurements and other existing data from the Atherosclerosis Prevention in Pediatric Lupus Erythematosus (APPLE) trial, we assessed interactions between serum 25-hydroxyvitamin D (25(OH)D), atorvastatin randomisation and CIMT progression rate. Methods: Participants in the 3-year APPLE trial were randomised to placebo or atorvastatin and CIMT progression rate was measured. Baseline frozen serum was used to measure 25(OH)D concentrations. Mixed effect longitudinal models for CIMT progression at 3 years were used to evaluate interaction between vitamin D deficiency (serum 25(OH)D

UR - http://www.scopus.com/inward/record.url?scp=84930194157&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84930194157&partnerID=8YFLogxK

U2 - 10.1136/lupus-2014-000037

DO - 10.1136/lupus-2014-000037

M3 - Article

AN - SCOPUS:84930194157

VL - 1

JO - Lupus Science and Medicine

JF - Lupus Science and Medicine

SN - 2053-8790

IS - 1

M1 - e000037

ER -